VERU

$2.41

Post-MarketAs of Mar 17, 8:00 PM UTC

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.41
Potential Upside
5%
Whystock Fair Value$2.53
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 fe...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-60.25%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.95

Recent News

GuruFocus.com
Feb 11, 2026

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Veru Inc (VERU) reports progress in clinical trials and financial fortification, despite ongoing profitability hurdles.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 11, 2026

Veru Inc. Q1 2026 Earnings Call Summary

Moby summary of Veru Inc.'s Q1 2026 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 11, 2026

Veru (VERU) Q1 2026 Earnings Call Transcript

With me on this morning's call are Doctor Gary Barnett, our Chief Scientific Officer, Michele Greco, our Chief Financial Officer and Chief Administrative Officer, Phil Greenberg, General Counsel, and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you for joining our first quarter fiscal year 2026 earnings call.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Dec 17, 2025

Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges

Veru Inc (VERU) reports significant progress in drug development and financial restructuring amid ongoing net losses and increased R&D expenses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Oct 8, 2025

October 2025's Noteworthy Penny Stocks

As the U.S. stock market rebounds with major indexes like the S&P 500 hitting new all-time highs, investors are keenly observing the Federal Reserve's recent interest rate cut amidst ongoing economic uncertainties. For those willing to explore beyond established giants, penny stocks—often representing smaller or newer companies—offer intriguing possibilities despite their somewhat antiquated label. In this article, we explore three penny stocks that showcase robust financial health and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.